SAGA Stock Recent News

VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discovery, announces the addition of 180 claims spanning 4,500-hectares, increasing the total size of the Radar Titanium-Vanadium (Ti-V) project from 17,250-hecatres to 21,750-hectares. This addition now encompasses the 20km inferred oxide zone starting from the 2025 Hawkeye drill program area heading west towards the new claim boundary.

VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discovery, is pleased to provide an update on the 2024 field program at the Legacy Lithium Project in James Bay, Quebec, operated by Rio Tinto Exploration Canada Inc. (RTEC). RTEC is a Canadian subsidiary of the Rio Tinto Group (LSE: RIO, ASX: RIO, NYSE: RIO).

VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SAGA Metals Corp. (“TSXV: SAGA”) (“SAGA” or the “Company”), a North American exploration company focused on critical mineral discovery in Canada, is pleased to announce the successful closing of its initial public offering (IPO) and provide updates on its major projects.

BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to falsely claim rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has erroneously and maliciously asserted claims to ITV-1 in attempts to mislead the investing public and to harm the shareholder value of SAGA as well as the former owner, Enzolytics, Inc. (PINK: ENZC). The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of SAGA.